Delving into the Latest Updates on RSVpreF with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

recombinant respiratory syncytial virus pre-fusion F protein, water for injections(Pfizer), Respiratory Syncytial Virus Subtype A Stabilized Prefusion F protein/Respiratory Syncytial Virus Subtype B Stabilized Prefusion F protein, Respiratory Syncytial Virus Vaccine

+ [6]

Target

RSV F protein

Action

modulators

Mechanism

Respiratory syncytial virus F protein modulators(Respiratory syncytial virus F protein modulators)

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Pneumonia due to respiratory syncytial virusRespiratory Syncytial Virus InfectionsLower Respiratory Tract Infections

Inactive Indication-

Originator Organization

Pfizer Inc.

Active Organization

Pfizer Pharmaceuticals Korea Ltd.

Pfizer Inc.

Pfizer Australia Pty Ltd.

+ [2]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Canada (04 Jan 2023),

Lower Respiratory Tract Infections

RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States)

Login to view timeline

This study will use a retrospective cohort design and will be conducted within routinely collected national healthcare and statutory demographic datasets held by PHS and National Records of Scotland (NRS). As such, there will be no active enrollment of study participants, no direct contact with study participants, no collection of any primary data outside of the standard of care (SOC), and no requirement for informed consent.
This study design was chosen due to several advantages, over other possible designs, including the ability to evaluate incidence of study outcomes in exposed and unexposed infants, ability to follow infants longitudinally to evaluate study outcomes through 12 months of age, and ability to evaluate all-cause outcomes.
Study endpoints, including RSV-associated LRTD hospitalization and RSV-associated hospitalization, among infants born to ABRYSVO-vaccinated mothers (exposed group) will be compared with those among infants born to ABRYSVO-unvaccinated mothers (comparison group) initially from birth through 6 months of age, with later analysis from birth through 12 months as the infants reach this age threshold and their data become available.

Start Date15 Oct 2026

Sponsor / Collaborator

Pfizer Inc.

NCT07839871

/ Not yet recruitingPhase 3

A PHASE 3 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS VACCINE IN CHILDREN AT HIGH RISK OF RSV DISEASE

The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of RSVpreF in children 5 to <18 years of age at high risk for RSV disease, including those who are immunocompromised.

Start Date28 Sep 2026

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with RSVpreF

Login to view more data

100 Translational Medicine associated with RSVpreF

Login to view more data

100 Patents (Medical) associated with RSVpreF

Login to view more data

493

Literatures (Medical) associated with RSVpreF

31 Dec 2026·Human Vaccines & Immunotherapeutics

Parental acceptability of new RSV preventive therapies for infants: A cross-sectional survey in Canada

Article

Author: Moss, Stephana Julia ; Lee, Janet S W ; Vadlamudi, Nirma Khatri ; Castillo, Eliana ; MacDonald, Shannon E ; Dubé, Ève ; Bolotin, Shelly ; Halperin, Scott A ; MacDonald, Jade ; Fitzpatrick, Tiffany ; Greyson, Devon ; Manca, Terra ; Buchan, Sarah A ; Comeau, Jeannette L ; Papenburg, Jesse ; Parsons Leigh, Jeanna ; Blanchard, Wade ; Halperin, Donna ; Langley, Joanne M ; Brousseau, Nicholas ; Brundin-Mather, Rebecca

Two new RSV immunization products exist for infants: a prenatal vaccine (RSVpreF) and a long-acting monoclonal antibody for infants (nirsevimab). While both showed promise in clinical trials, implementation has varied across jurisdictions. Before rollout in Canada, we conducted an anonymized, online survey with a nationally representative sample of 1,015 expectant and recent birth parents. The primary outcome was product acceptability (disagree, undecided, agree). Odds ratios (ORs) and 95% confidence intervals (CIs) identified factors associated with agreement or indecision versus disagreement. Approximately 49% (n = 499) were expecting; 51% (n = 516) had a baby in the past year. Overall, 72% (n = 727) agreed to receive a product: 61% (n = 624) for RSVpreF and 60% (n = 608) for nirsevimab. RSVpreF agreement was higher among older parents (e.g., OR = 3.64; 95% CI, 1.99-6.67 for age 25-34 versus 18-24 years), those with a university degree (OR = 3.65; 95% CI, 2.01-6.64 versus high school), higher income (OR = 2.31; 95% CI, 1.01-5.28 for ≥$150k versus <$40k), or receipt/intention for Tdap (OR = 3.76; 95% CI, 2.37-5.96 versus no receipt/intention) or influenza (OR = 2.04; 95% CI, 1.29-3.21) vaccines. Agreement was higher among parents of children without a high-risk medical condition compared to those with (OR = 2.32; 95% CI, 1.44-3.72). Similar trends were observed for nirsevimab, with lower agreement also noted among those who self-researched antibodies (OR = 0.51; 95% CI, 0.30-0.88 versus not). As most respondents rated product safety (76%), effectiveness (71%), and disease severity risk (70%) as important in decision-making, providing clear information on these, alongside communications targeted to subgroups with lower agreement, may optimize uptake as programs rollout.

31 Dec 2026·Expert Review of Vaccines

Cost-effectiveness of RSVpreF for the prevention of respiratory syncytial virus illness among high-risk adults in Germany

Article

Author: Sato, Reiko ; Quinn, Erin ; Bayer, Lea J. ; Lade, Caroline ; Schiffner-Rohe, Julia ; MacKinnon, Mary ; von Eiff, Christof ; Averin, Ahuva ; Friedrich, Josephine ; Freisberg, Severin

INTRODUCTION:

Vaccination against lower respiratory tract illness due to respiratory syncytial virus (RSV-LRTI) is approved in Europe for all adults aged ≥18 years. The German Standing Committee on Vaccination (STIKO), however, only recommends vaccination for high-risk adults aged 60-74 years and all adults aged ≥75 years (standard of care [SOC]). Younger, immunocompromised adults [IC], as well as those with chronic medical conditions [CMC+], remain unprotected.

RESEARCH DESIGN AND METHODS:

A multi-cohort model projected lifetime RSV-related clinical and economic outcomes (in 2025 €) among adults in Germany. Base case analyses considered the cost-effectiveness of adding vaccination of IC adults aged 18-59 years to the SOC from a societal perspective. An expanded base case adding CMC+/IC adults aged 18-59 years to the SOC was also evaluated.

RESULTS:

Adding IC adults aged 18-59 years to the recommendation would prevent 6,490 additional cases, avert 199 more deaths, and reduce costs by 21 million € compared to the SOC. Incorporating CMC+/IC adults would prevent 24,545 additional cases and 388 deaths, at an incremental cost of 238 million €.

CONCLUSIONS:

Expanding the recommendation to include IC or CMC+/IC adults aged 18-59 years could substantially reduce the clinical burden of RSV-LRTI in Germany; including IC 18-59-year-olds would also be cost-saving.

31 Dec 2026·Human Vaccines & Immunotherapeutics

5C psychological antecedents of vaccine hesitancy toward maternal RSV vaccines and infant monoclonal antibodies among pregnant and postpartum women and their partners in China: A multicenter, dyadic survey design, cross-sectional study

Article

Author: Xia, Wei ; Zhu, Xuan ; Wu, Jing ; Zhao, Guanlan ; Song, Peige ; Zhao, Yang ; Hou, Leying ; Liu, Xinyu ; Wang, Na ; Zhu, Yixiao

We assessed vaccine hesitancy toward two novel respiratory syncytial virus (RSV) immunization strategies, maternal vaccines and infant monoclonal antibodies (mAbs), among 4422 couples across eight Chinese provinces, via a multicenter cross-sectional survey with convenience sampling from medical institutions. Vaccine hesitancy was measured using the 5C scale (confidence, complacency, constraints, calculation, collective responsibility), with total scores (higher indicating lower hesitancy) as the primary outcome. Linear mixed-effects models analyzed sociodemographic and pregnancy-related factors. Women had marginally lower total 5C scores than partners for maternal vaccines (45.88 [SD 5.90] vs. 46.25 [5.74]; Cohen's d = -0.06, 95% CI: -0.09 to -0.03; p < .001), with no significant difference for mAbs. For both strategies, calculation scored highest in both sexes. Within-couple correlations across domains for the same strategy were low (r ranged from 0.31 to 0.48). In multivariable models, older age, rural residence and lower income were associated with greater hesitancy for both strategies (e.g. age: maternal vaccines, β = -0.09, 95% CI: -0.12 to -0.05; mAbs, β = -0.09, 95% CI: -0.12 to -0.06). Among women, third-trimester status and prior children were each independently associated with higher hesitancy. Prior influenza vaccination during pregnancy was associated with lower hesitancy toward maternal vaccines (β = 0.73, 95% CI: 0.32 to 1.13) but not mAbs. Ultimately, Chinese expectant and new parents show a hesitancy profile toward RSV immunization strategies dominated by active information-seeking. Prenatal counseling and broader communication efforts should include both parents. Efforts should prioritize older, rural, and lower-income couples.

406

News (Medical) associated with RSVpreF

06 Sep 2026

·www.prnewswire.com

Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults

-- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection -- -- Robust neutralizing antibody responses across RSV, hMPV and PIV3 in Phase 2 recapitulates Phase 1 results demonstrating best-in-class breadth (with no immune interference) and no drop-off in responses in the oldest participants (75+ years) -- -- Favorable safety & tolerability profile and successful 2,000L commercial-scale production further de-risk late-stage development and commercialization -- SHANGHAI, Sept. 6, 2026 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced positive preliminary data from a Phase 2 clinical trial in older adults in Australia evaluating SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) protein-based vaccine candidates based on prefusion-stabilized F (PreF)-Trimer subunit vaccine antigens utilizing Clover's validated Trimer-Tag vaccine technology platform. "We are pleased to announce positive Phase 2 clinical data strengthening the potential first-in-class and best-in-class profile for our RSV+hMPV±PIV3 combination vaccine candidates, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection," said Joshua Liang, Chief Executive Officer & Board Director of Clover. "The positive Phase 2 results significantly de-risk future late-stage development. Importantly, the results also continue to validate our differentiated Trimer-Tag platform for the development of multi-valent protein-based respiratory vaccines that have the potential to make an impact on public health and on chronic diseases caused by respiratory viruses[1]." The ongoing Phase 2 trial for Clover's combination vaccine candidates is a randomized, observer-blinded, multi-center study with 420 older adults (60-85 years) enrolled in Australia, and the participants have been randomized to receive either SCB-1022 (RSV + hMPV), SCB-1033 (RSV + hMPV + PIV3) or placebo. Immunogenicity Antibody titers (geometric mean titers [GMTs]) at 28 days post-vaccination in the Phase 2 were generally in-line with or trended higher than the prior Phase 1 trial. Geometric mean fold rises (GMFRs) in neutralizing antibodies (nAbs) at 28 days post-vaccination compared to pre-vaccination: RSV nAbs: Approximately 6-9 fold increases hMPV nAbs: Approximately 6-8 fold increases PIV3 nAbs: Greater than 3 fold increase (approximately 5 fold increase in participants with baseline PIV3 nAbs in the bottom tertile), driven by up to approximately 20 fold increases in PIV3 PreF-specific antibodies[2] No drop-off in antibody responses observed in the oldest participants (75+ years) compared to younger participants (60-74 years). No signs of immune interference on RSV and hMPV nAbs from the addition of PIV3 PreF antigen in SCB-1033 (RSV+hMPV+PIV3) compared to SCB-1022 (RSV+hMPV). Respiratory Tract Infections (Based on AE Reporting) Approximately 62% lower rate of respiratory tract infection was observed in the vaccine groups (SCB-1022 and SCB-1033) versus the placebo group within 28 days of vaccination based on AE reporting of any respiratory tract infections (no PCR sequencing of infection cases was conducted in the study). Significant RSV outbreak[3] with co-circulation[4] of hMPV and PIV in Australia occurred during the study enrollment and follow-up period. Safety and Reactogenicity SCB-1022 and SCB-1033 were generally well-tolerated; solicited local and systemic adverse events (AEs) within 7 days of vaccination were mostly mild and all transient. The most common solicited AEs were fatigue, headache and injection site pain, with mean durations of approximately 2 days for the vaccine groups (SCB-1022 and SCB-1033) and the placebo group. The frequency of unsolicited AEs within 28 days of vaccination was similar across the vaccine and placebo groups. There were no vaccine-related serious adverse events (SAEs), AEs of special interest (AESIs), or AEs leading to discontinuation. Commercial-Scale Manufacturing Scale-Up In parallel with the Phase 2 trial, Clover conducted commercial-scale 2,000L bioreactor scale-up production of multiple batches of Trimer-Tagged RSV, hMPV and PIV3 PreF antigen components of SCB-1022/1033. The successful 2,000L production process scale-up further de-risk future late-stage development and commercialization. Based on these positive Phase 2 results for the RSV + hMPV ± PIV3 combination vaccine candidates further validating the Trimer-Tag platform, Clover will continue to evaluate continued mid- and late-stage development plans as well as potential global collaboration opportunities for value maximization. About Clover Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing and commercial capabilities as well as strong partnerships with organizations globally, Clover has a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable.  Clover Forward-looking Statements This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate," "believe," "could," "estimate," "expect," "going forward," "intend," "may," "might," "ought to," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time. SOURCE Clover Biopharma 21% more press release views with Request a Demo

Phase 2VaccineClinical ResultPhase 1

25 Aug 2026

·allsci.com

CSPC's RSV vaccine clears FDA for US trials weeks after China approval

SYS6057, a recombinant respiratory syncytial virus (RSV) vaccine candidate developed by CSPC Pharmaceutical Group (HKEX: 01093), has received FDA clearance to begin clinical trials in the US, less than a month after China's National Medical Products Administration (NMPA) granted the same authorization on 30 July 2026. The back-to-back regulatory clearances give the Hong Kong-listed company a simultaneous development path in two of the world's largest markets for RSV prophylaxis in older adults. SYS6057 combines the RSV prefusion F (Pre-F) protein antigen with a proprietary second-generation nano-adjuvant system. CSPC says the adjuvant uses a different nanocarrier compared with its earlier RSV vaccine candidate, conferring distinct physicochemical and immunological properties. Preclinical data, according to the company, showed the vaccine can simultaneously elicit high-titre neutralising antibodies and cellular immune responses — a dual-arm immune profile the company attributes to adjuvant optimization. No clinical efficacy or safety data have been disclosed. The planned clinical development in both countries targets prevention of RSV-associated lower respiratory tract disease in adults aged 60 and older. Trial design, participant numbers, dosing, and primary endpoints have not been disclosed. CSPC enters a market where three RSV vaccines are already approved in the US for older adults: GSK's Arexvy (RSVPreF3-AS01E), Pfizer's Abrysvo (RSVpreF), and Moderna's mRESVIA (mRNA-1345), first approved in May 2023, May 2023, and May 2024, respectively. Arexvy and Abrysvo use prefusion F protein antigens, while mRESVIA uses mRNA encoding the prefusion F protein. SYS6057 similarly targets prefusion F but combines the recombinant antigen with CSPC's proprietary nano-adjuvant system, broadly resembling Arexvy's protein-plus-adjuvant strategy while using different adjuvant technology. CSPC describes SYS6057 as its second recombinant protein vaccine candidate to enter clinical trials. Spot something wrong? Report an issue with this article

VaccineDrug ApprovalmRNAINDClinical Study

04 Aug 2026

·firstwordpharma.com

Pfizer expands cost-cutting efforts with new $2.5B target

Pfizer is extending its cost-cutting drive again, this time with plans to unlock an additional $2.5 billion in savings between 2027 and 2029. That brings its total expected net savings from its various restructuring initiatives in recent years to $9.7 billion through 2029.The latest measures include $1 billion in further productivity savings from technology and simplification initiatives, as well as $1.5 billion from the next phase of its manufacturing optimisation programme, which will focus on network structure changes, enhancements to its product portfolio and more operational efficiencies."We have made meaningful progress on our productivity enhancement initiatives and remain on track to deliver most of the anticipated $7.2 billion in total net cost savings by the end of 2026," said Cecile Guegan, interim chief financial officer replacing Dave Denton, in prepared remarks during the company's second-quarter earnings call Tuesday.Eliquis, Padcev top estimatesThe announcement accompanied stronger-than-expected quarterly results. Overall revenues in the three months ended June were up 3% year-over-year to $15 billion, beating forecasts of $14.4 billion. Pfizer nevertheless reported a net loss of $248 million, versus net income of $2.9 billion in the corresponding year-ago quarter, due to $4.3 billion in non-cash asset impairments mostly tied to disappointing results from a Phase III lung cancer trial of sigvotatug vedotin.Regarding individual drug products, sales were led by the anticoagulant Eliquis, which climbed 21% to $2.4 billion, above analyst expectations of roughly $2 billion. Bladder cancer therapy Padcev, an antibody-drug conjugate Pfizer acquired through its $43-billion takeover of Seagen in 2023, also exceeded forecasts, with sales rising 23% to $667 million, topping consensus estimates of about $634 million.Other growth products included the Vyndaqel franchise (+9%, $1.8 billion), Nurtec ODT/Vydura (+18%, $421 million), Lorbrena (+41%, $354 million) and Abrysvo (+46%, $208 million).Lower COVID outlookHowever, COVID-19 products continued to weigh on results amid subdued demand. Sales of Pfizer's Comirnaty vaccine fell 32% to $261 million, while its Paxlovid treatment for COVID-19 infection plunged 95% to just $21 million. Pfizer lowered its full-year outlook for those products to a combined $4 billion, down from about $5 billion previously."Low COVID-19 incidence could continue to limit Paxlovid utilisation," Guegan said. "Our plan also assumes the majority of Comirnaty sales will occur toward year-end, consistent with the vaccination season."Despite the weaker COVID-19 product outlook, Pfizer did bump up the lower end of its 2026 revenue guidance to between $60.5 billion and $62.5 billion, from a previous range of $59.5 billion to $62.5 billion; it reaffirmed its adjusted earnings guidance of $2.80 to $3.00 per share. Management attributed the improved revenue outlook to a better-than-expected increase from its non-COVID portfolio of $1.5 billion.Pipeline cutsMeanwhile, Pfizer cleared some programmes from its pipeline. On the chopping block are MET-224o (PF-08656796), an oral, fully biased, ultra-long-acting GLP-1 receptor agonist in Phase I testing for chronic weight management. The company had acquired the compound through its hard-fought takeout of Metsera for $10 billion last year.It is also dropping development of another obesity candidate, PF-07976016, a GIP receptor antagonist that was in Phase II.Other discontinued programmes include PF-07985631, which was under development for nephropathy, and PF-07258669, an MC4R antagonist that Pfizer was working on to treat conditions like cachexia and anorexia-associated weight loss. Both of the programmes were in Phase I testing.

VaccinePhase 2Phase 1AcquisitionClinical Result

100 Deals associated with RSVpreF

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pneumonia due to respiratory syncytial virus	European Union	Pfizer Europe MA EEIG	23 Aug 2023
Pneumonia due to respiratory syncytial virus	Iceland	Pfizer Europe MA EEIG	23 Aug 2023
Pneumonia due to respiratory syncytial virus	Liechtenstein	Pfizer Europe MA EEIG	23 Aug 2023
Pneumonia due to respiratory syncytial virus	Norway	Pfizer Europe MA EEIG	23 Aug 2023
Respiratory Syncytial Virus Infections	United States	Pfizer Inc.	31 May 2023
Lower Respiratory Tract Infections	Canada	Pfizer Canada ULC	04 Jan 2023

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Respiratory Tract Infections	Phase 3	United States	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Japan	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Argentina	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Australia	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Brazil	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Canada	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Chile	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Denmark	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Finland	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Gambia	Pfizer Inc.	17 Jun 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06325657 (MORISOT, CTgov)	Phase 3	Respiratory Syncytial Virus Infections	681	RSVpreF (Maternal Participants: RSVpreF)	caglwomods = lzlabxslbs fmnwntolqk (aeyqtquaxa, lbchpgvdsw - yeryabojhq) View more	-	02 Jul 2026
				placebo+RSVpreF (Maternal Participants: Placebo)	caglwomods = lwzdgqasub fmnwntolqk (aeyqtquaxa, rgmlrykbmb - imkadggaxs) View more
NCT06593587 (CTgov)	Phase 3	Respiratory Syncytial Virus Infections	378	Placebo	ycjsunphwg = vmckidlkgg qcvzzumvhg (wylytgpwwi, rtgjwsztzk - dbyvcdlwuq) View more	-	09 Feb 2026
NCT06473519 (Amélie, CTgov)	Phase 3	Respiratory Syncytial Virus Infections	453	RSVpreF (RSVpreF (With Preservative, MDV))	tlclkkrkav(wtgvvutuqk) = kcixwjotyy uugbpfcgfb (xbglgjaqnc, uxwffybive - pzgzqpdgoh) View more	-	25 Sep 2025
				RSVpreF (RSVpreF (Without Preservative, SDV))	tlclkkrkav(wtgvvutuqk) = fsgmwxcnpv uugbpfcgfb (xbglgjaqnc, aaivdxtxgr - iszhnisnrq) View more
NCT05842967 (MONET, CTgov)	Phase 3	Respiratory Syncytial Virus Infections	885	SSA+RSVpreF (SSA: RSVpreF)	skbopnxdnk = pvdmmlysyk gylgstdhfc (ucrheuaxad, krnojhugcn - vsuxooyicq) View more	-	08 Aug 2025
				SSA (SSA: Placebo)	skbopnxdnk = kshieijmrt gylgstdhfc (ucrheuaxad, vmsgkoqshd - ymzwgiudga) View more
NCT04424316 (MATISSE, CTgov)	Phase 3	Respiratory Tract Infections	14,727	RSVpreF (Infant Participants: RSVpreF)	lyghmhkncl = iliarzltrx rjahnhbozc (ggqiicdtgz, vhbkzdzwui - pbaymjfmhy) View more	-	11 Feb 2025
				placebo+RSVpreF (Infant Participants: Placebo)	lyghmhkncl = kvzavgzdba rjahnhbozc (ggqiicdtgz, bikjnnmgto - mtjjlhjjyp) View more
NCT05035212 (2021-003693-31, Pubmed \| Clin Infect Dis)	Phase 3	-	-	Bivalent RSV Prefusion F (RSVpreF) Vaccine (RSVpreF 120-µg)	gsyfecqvvn(udoslybgem) = vaefyqlyds qpavsvgsme (ngueieebpx )	Positive	10 Feb 2025
				Bivalent RSV Prefusion F (RSVpreF) Vaccine (Placebo)	gsyfecqvvn(udoslybgem) = nxrgotxccz qpavsvgsme (ngueieebpx )
NCT04424316 (MATISSE, Pubmed \| Obstet Gynecol)	Phase 3	Obstetric Labor, Premature	-	Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVpreF)	vvjykwqgsf(fjplhdocdv) = no clinically significant increase in adverse events of special interest, including preterm birth, low birth weight, or neonatal hospitalization, was observed among pregnant people in the overall analysis ddqyrguruu (wbrqmbfpvm ) View more	Positive	01 Feb 2025
				Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine (Placebo)
NCT05842967 (MONeT, PipelineReview) Manual	Phase 3	Respiratory Syncytial Virus Infections	203	ABRYSVO	jskejowahv(fwvdhwjprn) = ABRYSVO was well-tolerated during the trial, showing a safety profile consistent with findings from other studies of the vaccine. uwkbfjhueq (tmbyqgoepm ) View more	Positive	12 Aug 2024
NCT04785612 (Phase 2a study, CTgov)	Phase 2	Respiratory Syncytial Virus Infections	70	RSVPreF (RSVPreF)	eldendlkcp(flohvznzti) = ccetzmimwk yoqtqkaojf (raabtfwduf, anngaothla - vsoaefznko) View more	-	07 Aug 2024
				Placebo (Placebo)	eldendlkcp(flohvznzti) = zduykvwxea yoqtqkaojf (raabtfwduf, qmazrmfjvq - vuubiergob) View more
NCT04424316 (MATISSE, Pubmed)	Phase 3	Respiratory Syncytial Virus Infections	-	RSVpreF vaccine	ymksqheanr(ptjpxwrioc) = okdfuitojd tgmccpdhgr (vbsarcjnbt ) View more	Positive	08 Jun 2024
				bivalent RSVpreF maternal vaccination (Placebo)	ymksqheanr(ptjpxwrioc) = kzoomsuogj tgmccpdhgr (vbsarcjnbt ) View more